BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region

9. November 2020 INDIZES WEUR

CASI’s pipeline expanded to include first-in-class monoclonal antibody developed to unlock anti-cancer immunity in liquid and solid …
(Orginal – Story lesen…)

Tags: atx cac ftse ibex omxs wig-20

You may also like...